 | |
| Company type | Public |
|---|---|
| Industry | |
| Predecessor | Jazz Pharmaceuticals, Inc. (before the 2012tax inversion to Ireland) |
| Founded | 2003; 23 years ago (2003) inCalifornia, U.S. |
| Headquarters | Dublin, Ireland |
Area served | Worldwide |
Key people | Bruce C. Cozadd (chairman andCEO) |
| Products | Pharmaceutical drugs |
| Brands | |
| Revenue |  US$3.83 billion (2023) |
| US$579 million (2023) | |
| US$415 million (2023) | |
| Total assets | US$11.4 billion (2023) |
| Total equity | US$3.74 billion (2023) |
Number of employees | c. 2,800 (2023) |
| Website | jazzpharma |
| Footnotes / references [1] | |
Jazz Pharmaceuticals plc (a merger ofJazz Pharmaceuticals, Inc. andAzur Pharma plc) is a globalbiopharmaceutical company with a focus ononcology andneuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.[2][3]
One of the company's considerable products is theUnited States Food and Drug Administration (FDA) approved drugXyrem (sodium oxybate), the sodium salt of the naturally occurringneurotransmitterγ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales.[1] In 2019, Jazz was granted FDA-approval to marketSunosi with indications for treatingexcessive daytime sleepiness (EDS) innarcolepsy as well asobstructive sleep apnea (OSA). In 2022, it was announced thatAxsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.[4]
In 2007, the company pled guilty to felony charges related to its illegal marketing ofXyrem foroff-label use.[5]
The company is also a member of thePharmaceutical Research and Manufacturers of America (PhRMA).[6]
On 18 February 2010, the FDA accepted a new drug application for JZP-6 (Sodium oxybate) for the treatment ofFibromyalgia.[7] In the following December, a new patent was issued for Sodium Oxybate.[8]
On September 19, 2011, Jazz Pharmaceuticals merged with Irish Azur Pharma plc to form Jazz Pharmaceuticals plc. The Azur Pharma seat inDublin became the headquarters of the combined company. Azur Pharma had been marketing specialty pharmaceutical products in thecentral nervous system (CNS) andwomen's health areas with US operations inPhiladelphia.[9][10]
On 26 April 2012, the company acquiredEUSA Pharma for $650 million (plus $50 million in milestone payments).[11] In September, the company sold its Women's Health business toMeda for $95 million.[12] In December, the company began clinical trial of intravenousErwinaze in patients withAcute Lymphoblastic Leukemia.[13]
In January 2014, the company announced it would acquire the rare disease drug developerGentium SpA and its lead productDefitelio for $1 billion.[14][15]
In May 2016, the company announced it would acquire Alizé Pharma II for $20.5 million.[16] At the end of the same month, the company announced its largest acquisition to date, with the purchase of Celator Pharmaceuticals for $1.5 billion.[17] As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia.[18]
In August 2019, the company announced it would acquire Cavion Inc. for up to $310 million.[19][20]
In January 2021, Jazz announced it would acquire cannabis-focused medicinal drug companyGW Pharmaceuticals for US$7.2 billion.[21][22] This acquisition added the medication Epidiolex (cannabidiol), developed to treat severe epilepsy syndromes, to the company's portfolio.[23][24]
In November 2025, Jazz Pharmaceuticals announced positive results from its Phase 3 trial for its cancer drug, Ziihera, a potential treatment for advanced gastroesophageal cancer.[25]
The following is an illustration of the company's mergers, acquisitions,spin-offs and historical predecessors:
